Peptide directoryGut, pancreas & liver

Gastrin-17

The stomach’s acid command, from the antrum to the acid-making cells.

Where it comes from

Made in
G cells of the gastric antrum and duodenum
Sent out by
Protein in the stomach, stretch of the stomach wall and vagal signals; acid in the antrum shuts it off
Acts on
  • Enterochromaffin-like cells (histamine release)
  • Parietal cells
  • Gastric lining (growth)

What it does

  • Drives acid secretion, mostly through histamine
  • Makes the acid-producing lining grow 1
  • Rises when acid is suppressed by proton-pump inhibitors or lost in atrophic gastritis 1

In medicine

  • Measured for gastrinoma (Zollinger-Ellison syndrome), where it runs very high
  • Pentagastrin, a synthetic fragment, was the acid-secretion test and a provocation test for medullary thyroid cancer; it is no longer made
  • Netazepide, a gastrin receptor blocker, has shrunk gastric neuroendocrine tumours in small trials 2

Beyond the body’s own use

  • Long-term proton-pump inhibitors raise gastrin several-fold. What that does to the stomach lining is still studied, and the moderate rises seen in practice have not been shown to cause cancer in people 1
  • Netazepide cleared every tumour in five of the patients in a year-long open trial in autoimmune atrophic gastritis, and the tumours grew back when it was stopped 2; it is not approved
  • A gastrin vaccine, G17DT, was taken into a randomised trial in 154 people with advanced pancreatic cancer and did not improve survival; it was never approved 3

Sources

  1. Rehfeld, Gastrin and the moderate hypergastrinaemias, International Journal of Molecular Sciences 2021
  2. Boyce et al., Netazepide can eradicate gastric neuroendocrine tumours, British Journal of Clinical Pharmacology 2017
  3. Gilliam et al., A randomised controlled trial of G17DT in pancreatic cancer, Pancreas 2012

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.